Monday, February 6, 2023 Daily Archives

IDT Biologika on the importance of oncolytic viruses in CGT development

by

IDT Biologika is a globally operating biopharmaceutical CDMO that specializes in the Contract Development and Manufacturing of vaccines, cell & gene therapeutics including oncolytic viruses, viral vectors, and other biologics for sterile liquid and lyophilized products. Through the utilization of our innovative technologies, we help our clients to advance their prophylactic and therapeutic products to treat serious diseases that impact human health worldwide. How IDT Biologika can support you with Cell & Gene Therapy inquiries was discussed in the following…

February 6, 2023

Sanofi: ‘Combining biopharma and vaccines ups manufacturing efficiency

by

Sanofi has combined manufacturing and supply chains across its pharma and vaccine in efforts to increase flexibility. As of the start of the year, Sanofi has combined its pharmaceutical and vaccine businesses from both a financial reporting and operations standpoint into a Biopharma segment, the French Pharma Giant said on its end-of-year call. The segment will include specialty care, general medicine, and vaccines, but not Sanofi’s consumer healthcare business. “Our pipeline being now mainly biologics, and [with] our new manufacturing…

February 6, 2023

BioNTech completes $43m pDNA facility in Germany

by

BioNTech says the completion of its first inhouse plasmid DNA (pDNA) facility in Marburg, Germany aims to increase manufacturing flexibility and support its oncology and COVID-19 pipeline. pDNA acts as an important starting material for the production of messenger RNA (mRNA) based therapeutic and vaccines, including cell therapies. The recently completed facility – which was acquired from Novartis in September 2020 – will enable BioNTech to independently manufacture pDNA for various clinical product candidates, as well as commercial products for…

February 6, 2023

Catalent shares jump 18% on Danaher acquisition rumor

by

A potential takeover of Catalent by life sciences giant Danaher could reflect Thermo Fisher’s 2017 buyout of Patheon according to analysts, who value the CDMO at $20+ billion. Danaher Corporation is eying up a potential bid for contract development and manufacturing organization (CDMO) Catalent, according to people familiar with the matter, Bloomberg reported this weekend. When contacted, a Catalent spokesperson told us: “As a matter of company policy, the Company does not comment on market rumors or speculation.” Catalent’s share…

February 6, 2023

Bionova to quadruple Fremont plant biologics capacity

by

Bionova Scientific has commissioned a third CDMO facility in Fremont, California, freeing space to quadruple manufacturing capacity at its nearby plant. Bionova, which fully transitioned into a contract development and manufacturing organization (CDMO) in November 2021, and was later acquired by Asahi Kasei Medical in April 2022, is set to begin the first phase of its strategic expansion. The firm already operates from two facilities in Fremont. One of the plants acts as its headquarters and the other is a development…

February 6, 2023